Your browser is no longer supported. Please, upgrade your browser.
Petros Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.62 Insider Own39.31% Shs Outstand9.83M Perf Week-46.83%
Market Cap34.31M Forward P/E- EPS next Y- Insider Trans34.84% Shs Float- Perf Month-63.08%
Income- PEG- EPS next Q- Inst Own5.60% Short Float- Perf Quarter-11.18%
Sales11.61M P/S2.96 EPS this Y36.70% Inst Trans34.31% Short Ratio0.13 Perf Half Y-52.52%
Book/sh1.82 P/B0.83 EPS next Y- ROA- Target Price- Perf Year-59.73%
Cash/sh0.36 P/C4.24 EPS next 5Y- ROE- 52W Range1.19 - 5.20 Perf YTD-54.65%
Dividend- P/FCF- EPS past 5Y- ROI-64.20% 52W High-70.96% Beta-
Dividend %- Quick Ratio0.40 Sales past 5Y- Gross Margin- 52W Low26.89% ATR0.48
Employees27 Current Ratio0.40 Sales Q/Q50.00% Oper. Margin- RSI (14)33.51 Volatility14.45% 13.92%
OptionableYes Debt/Eq0.10 EPS Q/Q70.90% Profit Margin- Rel Volume0.14 Prev Close1.66
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume18.51M Price1.51
Recom- SMA20-48.80% SMA50-43.48% SMA200-43.88% Volume2,591,273 Change-9.04%
Jan-18-22 09:20AM  
Jan-06-22 04:30PM  
Jan-05-22 01:38PM  
Dec-28-21 09:15AM  
Dec-22-21 09:10AM  
Dec-08-21 09:15AM  
Dec-02-21 12:00PM  
Nov-30-21 09:00AM  
Nov-15-21 04:30PM  
Nov-11-21 09:15AM  
Nov-08-21 09:15AM  
Nov-03-21 09:16AM  
Oct-21-21 09:25AM  
Oct-19-21 09:25AM  
Oct-14-21 09:00AM  
Sep-23-21 08:30AM  
Sep-10-21 08:30AM  
Aug-17-21 09:25AM  
Aug-16-21 08:30AM  
Aug-12-21 08:00AM  
Aug-11-21 10:39AM  
Jul-27-21 09:25AM  
Jul-13-21 09:15AM  
Jul-12-21 08:15AM  
Jun-02-21 10:12AM  
May-17-21 08:22AM  
May-14-21 08:30AM  
May-07-21 08:00AM  
Mar-18-21 09:00AM  
Feb-18-21 08:00AM  
Feb-04-21 08:30AM  
Jan-19-21 08:00AM  
Dec-08-20 04:15PM  
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. The company is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SHULMAN JOHN DDirectorDec 22Buy3.43145,773500,0015,703,544Jan 03 06:13 AM
SHULMAN JOHN DDirectorNov 29Buy3.00500,0001,500,0005,557,771Nov 30 02:49 PM
SHULMAN JOHN DDirectorOct 18Buy1.721,661,8072,849,9995,057,771Oct 21 08:47 AM